LINAC2022 - List of Authors (Hoeltermann, H.)

Paper	Title	Page
MOPOGE01	Linac Design within HITRIplus for Particle Therapy	134
	U. Ratzinger, H. Höltermann, B. Koubek, H. Podlech BEVATECH, Frankfurt, Germany M. Vretenar CERN, Meyrin, Switzerland
	Funding: EU Horizon 2020 Grant agreement No 101008548 Within the EU H2020 project HITRIplus for the development of cancer therapy with heavy ions a linac was designed. It is evolving from the concept of the 4 European cancer therapy centers applying light ions up to carbon. The new linac will in its simpliest version allow C⁴⁺ - beam injection into synchrotrons at 5 A MeV, with high beam transmission and allowing currents up to 5 mA alpha - particles. An advanced ECR - ion source will inject into an RFQ - IH-DTL combination. The DTL concept allows upgraded versions for A/q - values up to two and with beam energies of 7.1 A MeV from IH - tank2 and 10 A MeV from IH-tank3. The higher beam injection energies for light ions allow a relaxed synchrotron operation at lowest magnetic field levels. A main argument for the DTL extensions however is an additional linac function as radioisotope facility driver. The 7.1 A MeV are especially defined for the clean production of 211At, which may play a future role in cancer therapy. The linac will allow for high duty factors - up to 10%, to fulfil the needs for efficient radioisotope production. Solid state amplifiers with matched design RF power levels (up to 600 kW for IH3) will be used.
DOI •	reference for this paper ※ https://doi.org/10.18429/JACoW-LINAC2022-MOPOGE01
About •	Received ※ 24 August 2022 — Revised ※ 27 August 2022 — Accepted ※ 01 September 2022 — Issue date ※ 07 September 2022
Cite •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

Linac Design within HITRIplus for Particle Therapy

134

U. Ratzinger, H. Höltermann, B. Koubek, H. Podlech
BEVATECH, Frankfurt, Germany
M. Vretenar
CERN, Meyrin, Switzerland

Funding: EU Horizon 2020 Grant agreement No 101008548
Within the EU H2020 project HITRIplus for the development of cancer therapy with heavy ions a linac was designed. It is evolving from the concept of the 4 European cancer therapy centers applying light ions up to carbon. The new linac will in its simpliest version allow C⁴⁺ - beam injection into synchrotrons at 5 A MeV, with high beam transmission and allowing currents up to 5 mA alpha - particles. An advanced ECR - ion source will inject into an RFQ - IH-DTL combination. The DTL concept allows upgraded versions for A/q - values up to two and with beam energies of 7.1 A MeV from IH - tank2 and 10 A MeV from IH-tank3. The higher beam injection energies for light ions allow a relaxed synchrotron operation at lowest magnetic field levels. A main argument for the DTL extensions however is an additional linac function as radioisotope facility driver. The 7.1 A MeV are especially defined for the clean production of 211At, which may play a future role in cancer therapy. The linac will allow for high duty factors - up to 10%, to fulfil the needs for efficient radioisotope production. Solid state amplifiers with matched design RF power levels (up to 600 kW for IH3) will be used.

DOI •

reference for this paper ※ https://doi.org/10.18429/JACoW-LINAC2022-MOPOGE01

About •

Received ※ 24 August 2022 — Revised ※ 27 August 2022 — Accepted ※ 01 September 2022 — Issue date ※ 07 September 2022

Cite •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)